Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2005 December;47(4) > Panminerva Medica 2005 December;47(4):219-28

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

REVIEWS  


Panminerva Medica 2005 December;47(4):219-28

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Management of the metabolic syndrome

Grant R. W., Meigs J. B.

General Medicine Division Department of Medicine Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA


PDF  


The metabolic syndrome (MetS) represents the co-occurrence of insulin resistance, hypertension, central adiposity, atherogenic dyslipidemia, and a pro-inflammatory and pro-thrombotic state. Patients with this syndrome are at increased risk for the development of type 2 diabetes mellitus and cardiovascular disease. Epidemiologic studies reveal a prevalence of the MetS that increases with age and obesity. Patients with the MetS should be recognized as being at high risk for cardiovascular complications. Ongoing research focuses on the underlying pathophysiology of this disorder and the use of drug therapy to directly target insulin resistance and endothelial dysfunction. Currently, the standard of care includes active identification and aggressive management of traditional cardiovascular risk factors with an emphasis on healthy lifestyle changes to reduce weight and increase physical fitness.

top of page

Publication History

Cite this article as

Corresponding author e-mail